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In endemic areas, Plasmodium vivax relapses are difficult to distinguish from new infections. Genotyping of patients
who experience relapse after returning to a malaria-free area can be used to explore the nature of hypnozoite
activation and relapse. This paper describes a person who developed P. vivax malaria for the first time after
travelling to Boriziny in the malaria endemic coastal area of Madagascar, then suffered two P. vivax relapses
11 weeks and 21 weeks later despite remaining in Antananarivo in the malaria-free central highlands area. He was
treated with the combination artesunate + amodiaquine according to the national malaria policy in Madagascar.
Genotyping by PCR-RFLP at pvmsp-3α as well as pvmsp1 heteroduplex tracking assay (HTA) showed the same
dominant genotype at each relapse. Multiple recurring minority variants were also detected at each relapse,
highlighting the propensity for multiple hypnozoite clones to activate simultaneously to cause relapse.Background
In Madagascar, the combination of artesunate +
amodiaquine (ASAQ) is recommended since December
2005 as the first-line treatment for uncomplicated and non-
severe malaria, regardless of the parasite species involved.
One of the important differences between Plasmodium
falciparum and Plasmodium vivax is the formation of
hypnozoites that can cause relapses after a course of
treatment [1]. Such relapses have been described as
clonal in origin in individuals returning to non endemic
areas [2], but more recent evidence suggests that multiple
low-frequency variants commonly arise during relapse
[3,4]. In this report is described a case where sequential
P. vivax malaria relapses in a patient living in Antananarivo,
a malaria-free urban area, following ASAQ treatment
comprised multiple minority-variant parasites, suggesting
simultaneous reactivation of multiple hypnozoite clones.* Correspondence: milijaon@pasteur.mg
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From May to November 2010, a 23 year old Malagasy
man residing in Antananarivo travelled regularly to
Boriziny (north-western Madagascar) as a ground
transporter. He spent one to six nights there every
one to two weeks without taking precautions to prevent
mosquito bites. Antananarivo is the capital of Madagascar,
situated in the central highlands at 1,200 m above sea
level, and there is no malaria transmission throughout the
city [5]. Boriziny (previously named Port Berger) is in a
zone of tropical malaria transmission in north-western
Madagascar, situated at less than 40 m above sea level
(Figure 1). The subject returned from Boriziny on
November 19, 2010 and reported having fever and chills
on the evening of November 22, 2010. These symptoms
were accompanied by sweating and fatigue. On the morning
of November 23 (D0), he came to the malaria unit at the
Institut Pasteur de Madagascar (IPM). Thick and thin
peripheral blood smear were prepared, stained with Giemsa
and microscopically examined as previously described
[6]. Microscopy revealed P. vivax monoinfection with
a parasitaemia of 6,687 parasites/μl. According to theCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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Figure 1 Map of Madagascar showing the geographical
location of Boriziny and Antananarivo.
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Figure 2 Plasmodium vivax merozoite surface protein-3α (pvmsp-3α) r
digestion with the restriction enzymes Alu I (2A) and Hha I (2B). Lanes
D78, D150 P. vivax samples from the patient. DNA size markers are shown
molecular weight (base pairs); PC: positive control; NTC: negative control; B
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http://www.malariajournal.com/content/12/1/177malaria treatment policy in Madagascar, the patient was
treated with a combination of artesunate + amodiaquine
over three days (ASAQ Winthrop® for adults, artesunate
100 mg + amodiaquine 270 mg per tablet and 2 tablets per
day). The first dose of ASAQ for D0 was administered
under direct medical observation, with monitoring to
insure that the patient did not vomit. He was given the
ASAQ doses for D1 and D2 and was advised to return to
the laboratory if malaria symptoms recurred. The subject
spoke to staff from IPM on D1, D2 and D7 and reported
that all symptoms were completely resolved. Prior to drug
administration, as part of the national network for drug
resistance surveillance established in Madagascar since
1999 (authorization no. 517-SAN/SG/DLMT/SLP and
ethical clearance no. 013/04/SANPF/CAB), blood samples
were collected on filter paper and kept at −20°C until use.
Following the first malaria episode on November 23,
2010, the patient remained in Antananarivo and did not
travel back to Boriziny. However, on February 9, 2011
(D78), he developed fever and chills again and returned to
the malaria unit at IPM. Plasmodium vivax monoinfection
was confirmed by microscopy with a parasitaemia of 3,208
parasites/μl. Blood sample was collected on filter paper.
The patient was again treated with ASAQ as described.
The medical staff at IPM wanted to add primaquine to the
treatment but none was available in Madagascar.
After one week, the patient reported that symptoms
had completely resolved.
Again, the patient remained in Antananarivo, but on
April 22, 2011 (D150 with reference to the first attack in
November 2010), he experienced similar symptoms as
previously reported and returned to the the malaria unit
at IPM. Microscopy was performed and P. vivax
monoinfection was confirmed again with a parasitaemia100 bp
500 bp
1000 bp
B
D0 D78 D150C Blank MW
estriction fragment length polymorphism (RFLP) patterns after
PC positive control, NTC negative control, Blank without DNA and D0,
in lanes labelled MW with sizes shown in basepairs (bp). MW:
lank: without DNA.
Figure 3 Plasmodium vivax msp1 heteroduplex tracking assay
of the parasite isolates derived from the patient. Each lane
contains bands representing the sing-stranded HTA probe and
probe homoduplex (seen in the NTC and probe alone lanes). The
day of follow-up is indicated at the top of each lane. Unique
pvmsp1 genotypes A-D were identified as bands that migrated
differently from the single-stranded probe or probe homoduplex
bands and are marked as asterisks. These represent heteroduplexes
formed between the probe and amplified PCR product from each
patient sample. Asterisks are placed between shared
minority variants.
Andrianaranjaka et al. Malaria Journal 2013, 12:177 Page 3 of 5
http://www.malariajournal.com/content/12/1/177of 63 parasites/μl. A blood sample was collected on filter
paper, and the patient was treated with ASAQ for a third
time. After a week, the patient reported that symptoms
had completely resolved. Since November 2011, the
subject has been living in France and has reported no
further symptoms. Last contact was made with the
subject on January 16, 2013.
Plasmodium vivax genotyping
Parasite DNA extracted from filter paper blood samples
was analysed to compare the genotypic profile of the
P. vivax isolates collected from the patient during each
of the three malaria episodes. Using an Instagen kit
(Bio-Rad Laboratories Headquarters, France), DNA
was extracted from the blood spots. Nested-PCR was
used to confirm P. vivax monoinfection in the three
samples from D0, D78 and D150 [7]. DNA from P. vivax
collected from Maevatanana – a study site distant from
Boriziny, was used as positive control. Human DNA from
a blood donor from the HJRA University Hospital in
Antananarivo was used as negative control. The lack of
DNA contamination was checked using a blank (without
DNA) in each run.
Next, P. vivax isolates were typed at pvmsp-3α as
described elsewhere [8] to compare the D0, D78 and
D150 genotypes. Using PCR-RFLP with AluI and HhaI
restriction enzymes for pvmsp-3α, it was shown that the
dominant strain of P. vivax causing the malaria attacks at
D0, D78 and D150 was the same (Figure 2).
Plasmodium vivax infections are often polyclonal in
nature, harbouring more than one genetic strain or
variant at once [9,10]. The number of genetic variants
found simultaneously within a host is referred to as
the multiplicity of infection. To get a more nuanced
understanding of the multiplicity of infection within the
initial and relapsing isolates, a heteroduplex tracking assay
(HTA) targeting the highly variable P. vivax merozoite
surface protein 1 gene (pvmsp-1) as previously described
was used [3]. It was demonstrated that the initial as well
as two subsequent malaria episodes each harboured
multiple pvsmp1 variants by HTA, labelled Genotype A-D
in Figure 3, yielding multiplicity of infections (MOIs)
of 3–4. With each episode, genotype A remained the
dominant genotype, as implied by the darkness of the
band, while 2–3 other genotypes were detected as minority
variants. On D0, genotype C represents a minority variant
that recurred both 11 and 21 weeks later on D78
and D150. Genotype D, also found at D0, recurred
at D78, but was not detected at D150. Finally, genotype B
was not appreciated in the initial isolate, but appeared at
D78 and recurred at D150 (Figure 3). Taken together, this
pattern of multiple relapsing variants suggests that
polyclonal P. vivax infections reactivate hypnozoites
in a multiclonal fashion. While genotype B appearedas a novel variant at D78, possibly suggesting a new
infection from a mosquito inoculation, the clinical
history of the patient combined with the recurrence
of genotype B at D150 strongly suggest that genotype
B was present, but not appreciated in the initial D0
infection and achieved greater patency in the relaps-
ing infections. Because it is not certain that this is
the subject’s first bout of malaria, another possibility
is that genotype B represents a reactivated latent
hypnozoite from a prior P. vivax infection, preceding
November 2010.
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The case reported herein involves P. vivax malaria
imported from the coastal area to the central highland area
in Madagascar. Repetitive ASAQ treatment administered
according to the national malaria treatment policy was
effective in treating the acute illness in the patient but
relapses occurred twice. Parasitaemia was lower at each
subsequent attack. Pvmsp-3α genotyping indicated that the
same major strain was present during the three consecutive
attacks. However, such PCR-based genotyping can miss
other genotypes also present in low numbers. The HTA
analysis suggests that multiple other clones were involved
in the relapse.
Plasmodium vivax malaria is characterized by relapses
after resolution of the primary infection, derived from
activation of dormant hypnozoites in the liver [11].
The efficacy of ASAQ has been proven for treating
uncomplicated P. falciparum malaria [6] and P. vivax
malaria (Randrianarivelojosia, personal communication) in
Madagascar. Regarding the case reported in this paper,
P. vivax malaria occurring more than 70 days post-
treatment in a patient living in the central highland does
not indicate recrudescence due to ASAQ treatment failure;
rather, it is indicative of typical relapse. Plasmodium vivax
is the second most prevalent species of human malaria
parasite behind P. falciparum in Madagascar, but it occurs
in less than 5 % of biologically confirmed malaria cases
[12,13]. Thus, it is logical to give ACT universally for all
Plasmodium species whether P. falciparum or P. vivax.
However, P. vivax-specific treatment of hypnozoites in the
form of primaquine for radical cure is not the policy in
Madagascar. A subset of patients will suffer relapse as in
this gentleman. From a public health perspective, it would
be important eventually to take into account the use of
primaquine to eradicate dormant P. vivax hypnozites and
prevent these relapses.
To some degree, the level of genetic complexity seen
in malaria infections is associated with transmission
intensity. Even though P. falciparum dominates malaria
transmission in Madagascar, the detection of multiple
minority-variants of P. vivax in the reported case
suggests that genetic diversity of P. vivax parasites exists to
the extent that polyclonal P. vivax infections are not rare.
None of the minority variants detected evolved into the
predominant strain at relapse. However, the detection of
these minority variants allowed a more nuanced appreci-
ation of the mechanisms of hypnozoite activation within a
polyclonal infection. Simultaneous hypnozoite activation
and relapse of multiple clones promotes genetic diversity in
the parasite population as whole, and such relapse may be
an important mechanism for maintaining high P. vivax
genetic diversity even in areas of relatively low transmis-
sion. Furthermore, the ability to detect multiple recurring
strains of the same type can lend further evidence that arecurrent malaria episode indeed represents relapse rather
than new infection.
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